SMA News Forums Forums Treatments and Research Zolgensma (onasemnogene abeparvovec) Research Advancements and Adults With SMA: Column

  • rachel-markley

    July 10, 2019 at 1:22 pm

    I love this post! I think we really need to consider regenerative therapies and pay attention to Zolgensma’s effect on insurance coverage of long-term care. By regenerative therapy, I mean if you or I receive Zolgensma, our neurons and muscle fibers are already dead. How do we rebuild those to see more effects?

    I also worry about Medicaid saying “well, they received gene therapy so they clearly don’t need home care. Look at those babies, they’re fine!”

Log in to reply.